Related Experiment Video

Updated: Aug 18, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.9K

Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control

Niya Narayanan1, Dukhabandhu Naik2, Jayaprakash Sahoo3

  • 1Department of Endocrinology, Baby Memorial Hospital, Kozhikode 673005, Kerala, India.

World Journal of Virology
|December 9, 2022
PubMed

Insights

Dipeptidyl-peptidase-4 inhibitors (DPP-4i) show promise for treating COVID-19 in diabetic patients. These drugs may reduce mortality and infection severity through non-glycemic effects, including anti-inflammatory actions.

Area of Science:

  • Endocrinology
  • Infectious Diseases
  • Pharmacology

Background:

  • Diabetes mellitus increases COVID-19 mortality and complications.
  • Good glycemic control is crucial for managing COVID-19 in diabetic individuals.
  • Emerging evidence suggests Dipeptidyl-peptidase-4 inhibitors (DPP-4i) offer mortality benefits and anti-inflammatory effects in COVID-19 patients with diabetes.

Purpose of the Study:

  • To review the potential non-glycemic therapeutic effects of DPP-4i in diabetic patients with COVID-19.
  • To summarize current evidence on DPP-4i's role in mitigating COVID-19 severity beyond glycemic control.

Main Methods:

  • Literature review of studies investigating DPP-4i in diabetic patients with COVID-19.
  • Analysis of proposed mechanisms of action for DPP-4i, including viral entry inhibition, anti-inflammatory, and anti-fibrotic effects.

Main Results:

  • DPP-4i may reduce COVID-19 severity through multiple pathways.
  • Potential benefits include inhibition of viral entry and modulation of inflammatory and fibrotic responses.
  • Glycemic control is an additional benefit of DPP-4i therapy.

Conclusions:

  • DPP-4i represent a promising therapeutic strategy for COVID-19 in patients with diabetes.
  • Non-glycemic effects of DPP-4i warrant further investigation for managing COVID-19.
  • DPP-4i could offer a multifaceted approach to improving outcomes in this high-risk population.

Keywords:
COVID-19Diabetes mellitusDipeptidyl-peptidase-4Mortality

More Related Videos

Improving IV Insulin Administration in a Community Hospital12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
230
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
383
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
259
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
211
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
234
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
328